Clinical trials: Cisplatin, completed
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
This randomized phase III trial studies the side effects of paclitaxel when given together with cisplatin or topotecan with or without bevacizumab and to compare how well they work in treating patients with stage IVB, cervical…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
- Trial name
- NCT00803062
- Testing
- Bevacizumab, Cisplatin, Laboratory Biomarker Analysis
- Where
- 549 sites in United States, Spain
- Volunteers
- 452 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
Hypothesis We hypothesise that intermittent dosing of the anti-angiogenic RTKI sunitinib or bevacizumab prior to systemic cisplatin and gemcitabine chemotherapy to transiently "normalise" tumour vasculature in patients with…
- Trial name
- NCT01309633
- Testing
- 12.5mg sunitinib with Cisplatin and Gemcitabine, 25mg Sunitinib alternating with Cisplatin and Gemcitabine, 7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- National University Hospital, Singapore
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
This phase I clinical trial studies the side effects and best dose of veliparib when given together with paclitaxel and cisplatin and to see how well they work in treating patients with cervical cancer that has spread to other…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
- Trial name
- NCT01281852
- Testing
- Cisplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 25 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Inoperable Locally Advanced Non Small Cell Lung Cancer
Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.
A phase I trial is being conducted in patients with inoperable locally advanced NSCLC to treat with a combination of Conventional Fractionated Radiotherapy (CFRT) on the mediastinal lymph nodes and Stereotactic Ablative…
- Trial name
- N12HYB (NCT01933568)
- Testing
- SABR, Cisplatin
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- The Netherlands Cancer Institute
Cervical Cancer
Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
This study is an open-label, multicenter, multinational, two-arm, parallel randomized Phase 3 study evaluating the efficacy and safety of S-1+Cisplatin versus single-agent Cisplatin in patients with stage IVB, recurrent or…
- Trial name
- NCT00770874
- Testing
- S-1 + Cisplatin (arm A), Cisplatin (arm B)
- Where
- 4 sites in Japan, South Korea and 1 more
- Volunteers
- 375 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Gastric Cancer
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Patients with locally advanced resectable adenocarcinoma of the stomach or the esophagogastreal junction without previous therapy will be treated with one of two chemotherapy combinations before and after surgery.
- Trial name
- NCT01216644
- Testing
- 5-Fluorouracil, Leucovorin, Oxaliplatin
- Where
- Germany
- Volunteers
- 716 people
- Sponsor
- Krankenhaus Nordwest
Squamous Cell Carcinoma of the Head and Neck
Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to determinate the free-progression interval in patients with surgically resected locally advanced squamous cell carcinoma of head and neck treated with the maximum tolerated dose of the combination of…
- Trial name
- NCT00442455
- Testing
- Erlotinib chlorhydrate, Cisplatin, Radiation therapy
- Where
- 5 sites in Spain
- Volunteers
- 53 people
- Sponsor
- Grupo de Investigación Clínica en Oncología Radioterapia
Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT01064921
- Testing
- vorinostat, cisplatin, radiation therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lung Cancer
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00554463
- Testing
- Filgrastim, Pegfilgrastim, Etoposide
- Where
- 14 sites in United States
- Volunteers
- 5 people
- Sponsor
- Radiation Therapy Oncology Group
Stage IV Pancreatic Cancer
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
The primary objective of this study is to determine the efficacy of nab-paclitaxel plus cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma (PDA).
- Trial name
- NCT01893801
- Testing
- nab-paclitaxel, Cisplatin, gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Pancreatic Cancer Research Team
Non-small Cell Lung Cancer
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2 account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the results obtained by surgery alone or surgery…
- Trial name
- NCT00198367
- Testing
- Cisplatin-Gemzar, Cisplatin-Navelbine-Radiotherapy, Carboplatin-Taxol-Radiotherapy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Head and Neck Cancer
TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.
An Open Label Randomized, Multi-Centre Phase III Trial of TPF Chemotherapy Plus Concomitant Treatment With Cisplatin and Conventional Radiotherapy Versus TPF Chemotherapy Plus Concomitant Cetuximab and Conventional Radiotherapy…
- Trial name
- NCT00716391
- Testing
- TPF, radiotherapy and cisplatin., TPF, radiotherapy and cetuximab.
- Where
- 39 sites in Spain
- Volunteers
- 519 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Small Cell Lung Cancer, Non-small Cell Lung Cancer
An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the safety of CPT-11 plus platinum analogues (cisplatin, carboplatin and nedaplatin) regimens for patients with lung cancer, cervical cancer…
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer
- Trial name
- NCT01040312
- Testing
- CPT-11, Platinum analogues
- Where
- Japan
- Volunteers
- 321 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Head and Neck Cancer
Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002654
- Testing
- chemotherapy, cisplatin, low-LET cobalt-60 gamma ray therapy
- Where
- Switzerland
- Volunteers
- 224 people
- Sponsor
- Swiss Cancer Institute
Ovarian Cancer
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
RATIONALE: Chemosensitizers may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug.
- Trial name
- NCT00003214
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- 10 sites in Switzerland
- Volunteers
- 300 people
- Sponsor
- Swiss Cancer Institute
Lung Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with surgery may kill more tumor cells.
- Trial name
- NCT00003231
- Testing
- cisplatin, docetaxel, surgical procedure
- Where
- 9 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- Swiss Cancer Institute
Lung Cancer
Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells.
- Trial name
- NCT00030810
- Testing
- Hyperfractionated, Taxotere/Cisplatin, conventional surgery
- Where
- Switzerland
- Volunteers
- 46 people
- Sponsor
- Swiss Cancer Institute
Malignant Mesothelioma
Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00334594
- Testing
- Cisplatin, Pemetrexed, Therapeutic conventional surgery
- Where
- 13 sites in Germany, Switzerland
- Volunteers
- 153 people
- Sponsor
- Swiss Cancer Institute
Lung Cancer
Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00354549
- Testing
- bevacizumab + erlotinib hydrochloride, gemcitabine hydrochloride + cisplatin or carboplatin
- Where
- 2 sites in Switzerland
- Volunteers
- 104 people
- Sponsor
- Swiss Cancer Institute
Lung Cancer
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01116219
- Testing
- bevacizumab, erlotinib, bevacizumab, pemetrexed, cisplatin
- Where
- 22 sites in Switzerland
- Volunteers
- 149 people
- Sponsor
- Swiss Cancer Institute